NCT06659276Recruiting
Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma
Whole Body DWI Sequences As Compared with Standard FDG PET/CT in Patients with Simptomatic Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 26 Oct 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The primary objective is to evaluate the concordance of FDG PET/CT and total body DWI MRI sequences performed during staging and at the completion of therapy. Specifically, we will assess the positivity rates, both patient-based and lesion-based (total and by district), of the two methods during staging and at the completion of therapy. An interim analysis will be conducted comparing the two methods, followed by a final prognostic analysis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 83 (estimated)
- First submitted
- 24 Oct 2024
- Start date
- 1 Sept 2022
- Primary completion date
- Nov 2024
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Diseases
- Multiple myeloma
- NCT number
- NCT06659276
What you commit to
- Study type: Observational
- Planned participants: 83
- From 1 Sept 2022 to the primary completion date, Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients simultaneously affected by other neoplastic diseases or with a history of other neoplasms in the previous 5 years
- Age \< 18 years
- Women who are breastfeeding or pregnant
- Patients with metal implants or devices that constitute an absolute contraindication for MRI
- Patients with severe claustrophobia
- Patients with bone pain that prevents prolonged maintenance of the supine position
Who the study is looking for
- • Patients with symptomatic myeloma in the staging phase or with suspected symptomatic myeloma in the diagnostic phase
- Patients who have signed the informed consent form
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Policlinico S. Orsola Malpighi Coordinator of this site? Confirm its status | Bologna | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.